Clinical Trial Update: Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and efficacy of T-VEC in Japanese patients with unresectable stage IIIB-IV malignant melanoma has completed recruitment with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• T-VEC (talimogene laherparepvec)

Snippet

Sponsor: Amgen | Conditions: Unresectable Stage IIIB-IV Malignant Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2021-06-14